BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12536234)

  • 1. Analysis of HLA expression in human tumor tissues.
    Cabrera T; López-Nevot MA; Gaforio JJ; Ruiz-Cabello F; Garrido F
    Cancer Immunol Immunother; 2003 Jan; 52(1):1-9. PubMed ID: 12536234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.
    Maleno I; López-Nevot MA; Cabrera T; Salinero J; Garrido F
    Cancer Immunol Immunother; 2002 Sep; 51(7):389-96. PubMed ID: 12192539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
    Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
    Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells.
    Giorda E; Sibilio L; Martayan A; Moretti S; Venturo I; Mottolese M; Ferrara GB; Cappellacci S; Eibenschutz L; Catricalà C; Grammatico P; Giacomini P
    Cancer Res; 2003 Jul; 63(14):4119-27. PubMed ID: 12874016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural immunology and crystallography help immunologists see the immune system in action: how T and NK cells touch their ligands.
    Chen Y; Shi Y; Cheng H; An YQ; Gao GF
    IUBMB Life; 2009 Jun; 61(6):579-90. PubMed ID: 19472182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cell receptors as tools in cancer immunotherapy.
    Sentman CL; Barber MA; Barber A; Zhang T
    Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class I antigens and immune surveillance in transformed cells.
    Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
    Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
    Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
    Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance.
    Chang CC; Ferrone S
    Semin Cancer Biol; 2006 Oct; 16(5):383-92. PubMed ID: 16931041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy.
    Norris S; Doherty DG; Curry M; McEntee G; Traynor O; Hegarty JE; O'Farrelly C
    Cancer Immunol Immunother; 2003 Jan; 52(1):53-8. PubMed ID: 12536240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
    Baxevanis CN; Papamichail M
    Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma.
    Paschen A; Arens N; Sucker A; Greulich-Bode KM; Fonsatti E; Gloghini A; Striegel S; Schwinn N; Carbone A; Hildenbrand R; Cerwenka A; Maio M; Schadendorf D
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3297-305. PubMed ID: 16740750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dynamics of natural killer cell tolerance.
    Johansson MH; Höglund P
    Semin Cancer Biol; 2006 Oct; 16(5):393-403. PubMed ID: 16935000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC expression on human tumors--its relevance for local tumor growth and metastasis.
    Garrido F; Ruiz-Cabello F
    Semin Cancer Biol; 1991 Feb; 2(1):3-10. PubMed ID: 1912516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I.
    von Geldern M; Simm B; Braun M; Weiss EH; Schendel DJ; Falk CS
    Eur J Immunol; 2006 Sep; 36(9):2347-58. PubMed ID: 16909431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer.
    Bhan AK; DesMarais CL
    J Natl Cancer Inst; 1983 Sep; 71(3):507-16. PubMed ID: 6193308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.